CoChat

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Open access
Martinez-Lage, M., Torres-Ruiz, R., Puig-Serra, P., Moreno-Gaona, P., Martin, M. C., Moya, F. J., Quintana-Bustamante, O., Garcia-Silva, S., Carcaboso, A. M., Petazzi, P., Bueno, C., Mora, J., Peinado, H., Segovia, J. C., Menendez, P., Rodriguez-Perales, S. · 2020 · Nature Communications
Cited by 115

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor development. Because their expression is exclusive to cancer cells and their elimination induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However, specifically targeting the resulting chimeric products is challenging. Based on CRISPR/Cas9 technology, here we devise a simple, efficient and non-patient-specific gene-editing strategy through targeting of two introns of the genes involved in the rearrangement, allowing for robust disruption of the FO specifically in cancer cells. As a proof-of-concept of its potential, we demonstrate the efficacy of intron-based targeting of transcription factors or tyrosine kinase FOs in reducing tumor burden/mortality in in vivo models. The FO targeting approach presented here might open new horizons for the selective elimination of cancer cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-18875-x

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 115

Metadata

Authors
Martinez-Lage, M., Torres-Ruiz, R., Puig-Serra, P., Moreno-Gaona, P., Martin, M. C., Moya, F. J., Quintana-Bustamante, O., Garcia-Silva, S., Carcaboso, A. M., Petazzi, P., Bueno, C., Mora, J., Peinado, H., Segovia, J. C., Menendez, P., & Rodriguez-Perales, S.
Venue
Nature Communications
Published
2020-10-08
Volume
11
Issue
1
Pages
5060-5060
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3092292522
Cited by
115
References
14
FWCI
4.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. https://app.cochat.ai/papers/10.1038/s41467-020-18875-x
The paper
Martinez-Lage, M., Torres-Ruiz, R., Puig-Serra, P., Moreno-Gaona, P., Martin, M. C., Moya, F. J., Quintana-Bustamante, O., Garcia-Silva, S., Carcaboso, A. M., Petazzi, P., Bueno, C., Mora, J., Peinado, H., Segovia, J. C., Menendez, P., & Rodriguez-Perales, S. (2020). In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nature Communications. https://doi.org/10.1038/s41467-020-18875-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.